Should We Embrace Vaccines for Treating Substance- Related Disorder, A Subset of Reward Deficiency Syndrome (RDS)?

Blum, Kenneth; Badgaiyan, Rajendra D.; Angres, Daniel H.; Gold, Mark S.; Diagnostics, Dominion

doi:10.17756/jrds.2015-001

Cited by 2 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Relevant papers that explored the mechanisms shared between drug and food addiction, reviewed research into substance vaccination [ 55 ], gene therapy [ 56 ] and pro-dopaminergic regulation therapy for all RDS behaviors [ 57 ] have been published. Since the 80’s up until the present time, Blum’s group has published close to 35 peer-reviewed articles showing clinical benefits of KB220 variants [ 58 ] especially for craving behaviors [ 59 ].…”

Section: Treatment Results With Kb220mentioning

confidence: 99%

Pro-Dopamine Regulator - (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome (RDS)

Blum

Febo

Fried³

et al. 2017

J Reward Defic Syndr Addict Sci

Self Cite

View full text Add to dashboard Cite

We are faced with a worldwide opiate/opioid epidemic that is devastating. According to the Centers for Disease Control and Prevention (CDC), at least 127 people, young and old, are dying every day in America due to narcotic overdose. The Food and Drug Administration (FDA) has approved Medication-Assisted Treatments (MATs) for opiate/opioids as well as alcohol and nicotine. The mechanism of action of most MATS favors either blocking of dopaminergic function or a form of Opiate Substitution Therapy (OST). These treatment options are adequate for short-term treatment of the symptoms of addiction and harm reduction but fail long-term to deal with the cause or lead to recovery. There is a need to continue to seek better treatment options. This mini-review is the history of the development of one such treatment; a glutaminergic-dopaminergic optimization complex called KB220. Growing evidence indicates that brain reward circuitry controls drug addiction, in conjunction with “anti-reward systems” as the “anti-reward systems” can be affected by both glutaminergic and dopaminergic transmission. KB220 may likely alter the function of these regions and provide for the possible eventual balancing the brain reward system and the induction of “dopamine homeostasis.” Many of these concepts have been reported elsewhere and have become an integral part of the addiction science literature. However, the concise review may encourage readership to reconsider these facts and stimulate further research focused on the impact that the induction of “dopamine homeostasis” may have on recovery and relapse prevention.

show abstract

Section: Treatment Results With Kb220mentioning

confidence: 99%

Pro-Dopamine Regulator - (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome (RDS)

Blum

Febo

Fried³

et al. 2017

J Reward Defic Syndr Addict Sci

Self Cite

View full text Add to dashboard Cite

show abstract

“…In a number of articles we have suggested a novel approach that could have clinical importance called “Reward Deficiency Solution System™” [ 70 ] and provided rationale for the coupling of genetic testing [ 71 ], exploration of various treatment approaches utilizing Comprehensive Analysis of reported Drugs (CARD) ™ [ 72 ] and incorporation of a genomic-based putative dopaminergic agonist KB220z that has been shown to restore resting state functional connectivity in abstinent heroin addicts [ 73 ]. Two major therapeutic platforms involving anti-drug vaccines [ 74 ] and gene therapy [ 75 ] have also been recently addressed with cautious consideration.…”

Section: Future Perspectivesmentioning

confidence: 99%

Common Neurogenetic Diagnosis and Meso-Limbic Manipulation of Hypodopaminergic Function in Reward Deficiency Syndrome (RDS): Changing the Recovery Landscape

Blum

Febo²,

Badgaiyan³

et al. 2017

Self Cite

View full text Add to dashboard Cite

Background: In 1990, Blum and associates provided the first confirmed genetic link between the DRD2 polymorphisms and alcoholism. This finding was based on an earlier conceptual framework, which served as a blueprint for their seminal genetic association discovery they termed “Brain Reward Cascade.” These findings were followed by a new way of understanding all addictive behaviors (substance and non-substance) termed “Reward Deficiency Syndrome” (RDS). RDS incorporates a complex multifaceted array of inheritable behaviors that are polygenic.Objective: In this review article, we attempt to clarify these terms and provide a working model to accurately diagnose and treat these unwanted behaviors.Method: We are hereby proposing the development of a translational model we term “Reward Deficiency Solution System™” that incorporates neurogenetic testing and meso-limbic manipulation of a “hypodopaminergic” trait/state, which provides dopamine agonistic therapy (DAT) as well as reduced “dopamine resistance,” while embracing “dopamine homeostasis.”Result: The result is better recovery and relapse prevention, despite DNA antecedents, which could impact the recovery process and relapse. Understanding the commonality of mental illness will transform erroneous labeling based on symptomatology, into a genetic and anatomical etiology. WC: 184.

show abstract

Should We Embrace Vaccines for Treating Substance- Related Disorder, A Subset of Reward Deficiency Syndrome (RDS)?

Cited by 2 publications

References 26 publications

Pro-Dopamine Regulator - (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome (RDS)

Pro-Dopamine Regulator - (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome (RDS)

Common Neurogenetic Diagnosis and Meso-Limbic Manipulation of Hypodopaminergic Function in Reward Deficiency Syndrome (RDS): Changing the Recovery Landscape

Contact Info

Product

Resources

About